Qualitative analysis of interviews and focus groups exploring factors contributing to adherence to GnRH agonists in men with prostate cancer



This article was originally published here

Nurses Semin Oncol. December 14, 2021: 151236. doi: 10.1016 / j.soncn.2021.151236. Online ahead of print.

ABSTRACT

OBJECTIVES: Side effects of prolonged use of gonadotropin releasing hormones (GnRH) may lead to treatment nonadherence in men with advanced prostate cancer (PCa). We investigated the contributing reasons for non-adherence to GnRH agonists through interviews with men with PCa and focus groups with their healthcare professionals.

DATA SOURCES: The three stages of the study were theme validation, interviews with men about GnRH agonists, and focus groups with oncology specialists and clinical nurse specialists. An experienced oncologist validated the factors contributing to nonadherence identified in the literature. A total of 10 men with PCa were recruited from a large teaching hospital and interviewed individually using a topic guide. In the third step, two separate focus groups were held with oncology specialists and clinical nurse specialists treating men with PCa. Interviews and focus groups were recorded and transcribed verbatim. The initial codes identified from the third step were grouped into themes and analyzed thematically.

CONCLUSION: Themes identified from the interviews and focus groups influencing treatment adherence were treatment side effects, patient’s belief system, benefit outweighs harm, quality of life over quantity of life, social support and the patient-clinician relationship. Although side effects such as hot flashes and loss of libido were sometimes overwhelming for many, these men felt that the benefits of treatment outweighed the damage.

IMPLICATIONS FOR NURSING PRACTICE: The reasons leading to nonadherence can be multifactorial and unique to each patient. The use of different strategies by healthcare professionals can lead to the eventual acceptance of treatment, while recognizing the reasons for their non-adherence.

PMID:34920915 | DO I:10.1016 / j.soncn.2021.151236


Previous Stantec Inc - Consensus Says Potential of -48.7% Down
Next Omicron variant in Andhra Pradesh: Fever investigations at the center of Omicron's concerns | Vijayawada News